| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Sarar Mohamed | |
| P2860 | cites work | Disorders of carnitine transport and the carnitine cycle | Q24658342 |
| Long-term correction of urea cycle disorders | Q28142173 | ||
| Type I glutaric aciduria, part 1: natural history of 77 patients | Q28190649 | ||
| Short-chain acyl-coenzyme A dehydrogenase deficiency | Q28299438 | ||
| Application of electrospray tandem mass spectrometry to neonatal screening | Q33637060 | ||
| Liver transplantation in maple syrup urine disease | Q33797833 | ||
| Practical management of hyperinsulinism in infancy | Q33844337 | ||
| Neonatal onset ornithine transcarbamylase deficiency: A retrospective analysis | Q33854200 | ||
| A randomized study of alglucosidase alfa in late-onset Pompe's disease | Q34110220 | ||
| Nontransplant treatment of tyrosinemia | Q34171045 | ||
| Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry: results, outcome, and implications | Q34201641 | ||
| Problems in the management of urea cycle disorders | Q34309483 | ||
| The pathophysiology and treatment of hereditary tyrosinemia type 1. | Q34464154 | ||
| Classical galactosaemia revisited. | Q34547104 | ||
| Clinical approach to treatable inborn metabolic diseases: an introduction | Q34568220 | ||
| Clinical approach to inherited metabolic disorders in neonates: an overview | Q34690922 | ||
| The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature | Q35191008 | ||
| N-carbamylglutamate augments ureagenesis and reduces ammonia and glutamine in propionic acidemia | Q35813392 | ||
| Medications used in the treatment of hypoglycemia due to congenital hyperinsulinism of infancy (HI). | Q36385970 | ||
| Congenital hyperinsulinism associated ABCC8 mutations that cause defective trafficking of ATP-sensitive K+ channels: identification and rescue | Q36428374 | ||
| Mechanisms of Disease: advances in diagnosis and treatment of hyperinsulinism in neonates | Q36688366 | ||
| Cardiomyopathy and carnitine deficiency | Q36725320 | ||
| Hyperammonemia in the ICU. | Q36969948 | ||
| Pompe's disease | Q37302098 | ||
| Inborn errors of metabolism: part 1: overview | Q37429320 | ||
| Recognition and diagnostic approach to acute metabolic disorders in the neonatal period | Q38919289 | ||
| History of pediatric liver transplantation. Where are we coming from? Where do we stand? | Q39221296 | ||
| Classic galactosemia: dietary dilemmas | Q42703164 | ||
| Effect of continuous glucose therapy with uncooked cornstarch on the long-term clinical course of type 1a glycogen storage disease | Q44175104 | ||
| The impact of screening for propionic and methylmalonic acidaemia | Q44637489 | ||
| Long-term outcome of patients with urea cycle disorders and the question of neonatal screening | Q44666944 | ||
| Survival after treatment with phenylacetate and benzoate for urea-cycle disorders | Q45086096 | ||
| Newborn screening for hepatorenal tyrosinemia by tandem mass spectrometry: analysis of succinylacetone extracted from dried blood spots | Q45118951 | ||
| NTBC treatment in tyrosinaemia type I: long-term outcome in French patients | Q46795326 | ||
| Treatment of the acute crisis in maple syrup urine disease | Q46878544 | ||
| Decline of acute encephalopathic crises in children with glutaryl-CoA dehydrogenase deficiency identified by newborn screening in Germany | Q48109528 | ||
| Maple syrup urine disease: favourable effect of early diagnosis by newborn screening on the neonatal course of the disease | Q48480653 | ||
| Reduced incidence of severe metabolic crisis or death in children with medium chain acyl-CoA dehydrogenase deficiency homozygous for c.985A>G identified by neonatal screening | Q48551995 | ||
| Pharmacological rescue of carnitine transport in primary carnitine deficiency. | Q50731810 | ||
| Expanded newborn screening: outcome in screened and unscreened patients at age 6 years. | Q51819165 | ||
| Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I). | Q51952874 | ||
| Automated tandem mass spectrometry for mass newborn screening for disorders in fatty acid, organic acid, and amino acid metabolism. | Q54429818 | ||
| N-acetylglutamate synthetase deficiency: favourable experience with carbamylglutamate. | Q54607147 | ||
| Outcome of neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency in Australia: a cohort study. | Q55042915 | ||
| Persistent hyperinsulinemic hypoglycemia of infancy: Long-term octreotide treatment without pancreatectomy | Q57499787 | ||
| Advances in Diagnosis and Treatment of Hyperinsulinism in Infants and Children | Q63384416 | ||
| Neonatal hemodialysis: effective therapy for the encephalopathy of inborn errors of metabolism | Q68694133 | ||
| Tandem spectrometry in newborn screening | Q77663531 | ||
| The tandem mass spectrometry newborn screening experience in North Carolina: 1997-2005 | Q83120524 | ||
| Inborn errors of metabolism: part 2: specific disorders | Q83596885 | ||
| Acid-base disorders | Q84245616 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 6-13 | |
| P577 | publication date | 2011-01-01 | |
| P1433 | published in | Sudanese journal of paediatrics | Q27727494 |
| P1476 | title | Treatment strategies for acute metabolic disorders in neonates | |
| P478 | volume | 11 |
Search more.